Wilfredo Villarrubia, PA
Medical · West Columbia, SCNPI 1568992030
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.
Across 126 payments — averaging $37.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Amgen$801
- Johnson & Johnson$316
- Janssen Scientific Affairs, LLC$268
- AbbVie$244
- plus $851 from 18 others
What the payments were for
- Food & beverage$4,50296%
- Education$2034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 17 | $1,113 |
| GSK | 39 | $1,112 |
| Amgen | 21 | $801 |
| Johnson & Johnson | 4 | $316 |
| Janssen Scientific Affairs, LLC | 2 | $268 |
| AbbVie | 9 | $244 |
| UCB, Inc. | 7 | $153 |
| Aurinia Pharma U.S., Inc. | 3 | $141 |
| Grifols USA, LLC | 2 | $92 |
| Fresenius Kabi USA, LLC | 3 | $80 |
| Lilly USA, LLC | 3 | $52 |
| Organon | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $45 |
| Almatica Pharma LLC | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Radius Health, Inc. | 1 | $24 |
| Sanofi | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Sandoz | 1 | $20 |
| Pfizer | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,705 in reported general payments places this provider in the 85th percentile of 384 medical providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 640 | $5,683,211 |
| Enbrel SureclickEtanercept | 384 | $3,255,784 |
| RinvoqUpadacitinib | 123 | $946,664 |
| Orencia ClickjectAbatacept | 137 | $860,459 |
| NucalaMepolizumab | 117 | $716,374 |
| XolairOmalizumab | 213 | $650,558 |
| Enbrel MiniEtanercept | 78 | $650,064 |
| XeljanzTofacitinib Citrate | 93 | $625,382 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 67 | $455,217 |
| Dupixent PenDupilumab | 110 | $455,027 |
| Xeljanz XrTofacitinib Citrate | 66 | $450,536 |
| BenlystaBelimumab | 55 | $277,193 |
| Humira(Cf)Adalimumab | 19 | $272,483 |
| Actemra ActpenTocilizumab | 59 | $269,441 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $247,797 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Savella | $244 | $1,227,497157 claims |
| GSKNucala, Benlysta, Trelegy Ellipta, Breo Ellipta | $1,112 | $1,093,262325 claims |
| PfizerXeljanz | $15 | $625,38293 claims |
| Johnson & JohnsonSimponi, Stelara, Tremfya | $316 | $523,68455 claims |
| AmgenEnbrel, Otezla, Prolia | $801 | $403,68780 claims |
| AstraZenecaTezspire, Symbicort | $1,113 | $252,65188 claims |
| UCB, Inc.Cimzia (2 Pack) | $153 | $183,62822 claims |
| SanofiKevzara | $24 | $101,46118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 medical providers in South Carolina.
Other medical in West Columbia
- Suzanne SmithWest Columbia$39K
- Anna ScottWest Columbia$16K
- Michelle EvansWest Columbia$9K
- Morgan ArmstrongWest Columbia$6K
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.